Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2021/6662476 http://scihub22266oqcxt.onion/10.1155/2021/6662476 34239576!8214485!34239576     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Environ+Public+Health 2021 ; 2021 (ä): 6662476 Nephropedia Template TP {{tp|p=34239576|t=2021. The Impact of Comorbidities on the Outcomes of Egyptian COVID-19 Patients: A Follow-Up Study |pdf=|usr=}}{{34239576}} gab.com Text The Impact of Comorbidities on the Outcomes of Egyptian COVID-19 Patients: A Follow-Up Study JO: J Environ Public Health http://www.kidney.de/pget.php?&tw=1&pmid=34239576 #FOAvip OBJECTIVES: This study evaluated the clinical manifestation of COVID-19 and adverse outcomes in patients with comorbidities (outcome: death). METHODS: A comparative follow-up investigation involving 148 confirmed cases of COVID-19 was performed for a month (between April and May 2020) at Qaha Hospital to describe the clinical characteristics and outcomes resulting from comorbidities. Participants were divided into two clusters based on the presence of comorbidities. Group I comprised cases with comorbidities, and Group II included subjects without comorbidity. Survival distributions were outlined for the group with comorbidities after the follow-up period. RESULTS: Fever (74.3%), headache (78.4%), cough (78.4%), sore throat (78.4%), fatigue (78.4%), and shortness of breath (86.5%) were the most prevalent symptoms observed in COVID-19 patients with comorbidities. Such patients also suffered from acute respiratory distress syndrome (37.8%) and pneumonia three times more than patients without comorbidities. The survival distributions were statistically significant (chi-square = 26.06, p </= 0.001). CONCLUSION: Multiple comorbidities in COVID-19 patients are linked to severe clinical symptoms, disease complications, and critical disease progression. The presence of one or more comorbidities worsened the survival rate of patients. Twit Text FOAVip The Impact of Comorbidities on the Outcomes of Egyptian COVID-19 Patients: A Follow-Up Study ????J Environ Public Health http://www.kidney.de/pget.php?&tw=1&pmid=34239576 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34239576 #FOAvip English Wikipedia <ref>{{Cite pmid|34239576}}</ref> The Impact of Comorbidities on the Outcomes of Egyptian COVID-19 Patients: A Follow-Up Study #MMPMID34239576 Albadawy RM; Jadoon BA; Mogahed MM; Ibrahim ME; Essawy TS; Amin AMA; Abd-Elraouf MS; Elawady MA J Environ Public Health 2021[]; 2021 (ä): 6662476 PMID34239576show ga OBJECTIVES: This study evaluated the clinical manifestation of COVID-19 and adverse outcomes in patients with comorbidities (outcome: death). METHODS: A comparative follow-up investigation involving 148 confirmed cases of COVID-19 was performed for a month (between April and May 2020) at Qaha Hospital to describe the clinical characteristics and outcomes resulting from comorbidities. Participants were divided into two clusters based on the presence of comorbidities. Group I comprised cases with comorbidities, and Group II included subjects without comorbidity. Survival distributions were outlined for the group with comorbidities after the follow-up period. RESULTS: Fever (74.3%), headache (78.4%), cough (78.4%), sore throat (78.4%), fatigue (78.4%), and shortness of breath (86.5%) were the most prevalent symptoms observed in COVID-19 patients with comorbidities. Such patients also suffered from acute respiratory distress syndrome (37.8%) and pneumonia three times more than patients without comorbidities. The survival distributions were statistically significant (chi-square = 26.06, p |*Comorbidity[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19/*epidemiology/*mortality[MESH] |Cause of Death[MESH] |Egypt/epidemiology[MESH] |Female[MESH] |Follow-Up Studies[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Mortality[MESH] |Pneumonia/*epidemiology/*mortality[MESH] |Respiratory Distress Syndrome/*epidemiology/*mortality[MESH] |SARS-CoV-2[MESH]The Impact of Comorbidities on the Outcomes of Egyptian COVID-19 Patie(epmc).pdf DeepDyve Pubget Overpricing